Navigation Links
ViroPharma to Participate in Several Upcoming Healthcare Investor Conferences

EXTON, Pa., Oct. 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William Roberts, vice president, corporate communications of ViroPharma, will present at the Oppenheimer 21st Annual Healthcare Conference at 3:55 P.M. ET on Tuesday, November 2, 2010.  The conference is being held at the Waldorf=Astoria in New York City.

Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Lazard Capital Markets 7th Annual Healthcare Conference at 1:45 P.M. ET on Wednesday, November 17, 2010.  The conference is being held at the St. Regis Hotel in New York City.

Mr. Rowland will also present at the 4th Annual Maxim Group Growth Conference at 9:30 A.M. ET on Thursday, November 18, 2010.  The conference is being held at the Grand Hyatt in New York City.

ViroPharma's presentations will be webcast live for investors through and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers to employees.  ViroPharma commercializes Cinryze™ (C1 esterase inhibitor [human]) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE).  ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information on ViroPharma's commercial products, please download the package inserts at  ViroPharma currently focuses its drug development activities in diseases including C1 esterase inhibitor deficiency and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, The company encourages investors to consult these sections for more information on ViroPharma and our business.

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViroPharma Receives Complete Response Letter for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Supplement
2. ViroPharma to Release 2010 Third Quarter Financial Results on October 27, 2010
3. ViroPharma to Present at the Jefferies 2010 Global Healthcare Conference
4. ViroPharma Announces Presentation of Data from Non-Toxigenic Clostridium difficile (VP20621) Phase 1 Study
5. ViroPharma To Participate in Two September Healthcare Investor Conferences
6. ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
7. ViroPharma Files Prior Approval Supplement (PAS) for Cinryze™ (C1 Esterase Inhibitor [Human]) Industrial Scale Manufacturing
8. ViroPharma to Participate in Two June Healthcare Investor Conferences
9. ViroPharma To Host Investor Day
10. ViroPharma to Participate in the Cowen and Company 30th Annual Healthcare Conference
11. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2009 Financial Results
Post Your Comments:
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... Nov. 25, 2015 ... of the "Global Brain Monitoring Devices ... --> ) has announced ... Monitoring Devices Market 2015-2019" report to ... Markets ( ) has announced the ...
(Date:11/25/2015)... 2015  Linden Care, LLC, a retail specialty pharmacy ... patients suffering from chronic pain, said today that it ... Order (TRO) enjoining Express Scripts from unilaterally terminating the ... --> --> The company said ... options. --> --> ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, ... ... online platform for mental health and wellness consultation, has collaborated with Women’s ... holistically address their reader’s queries on topics on mental and emotional well-being ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional and far-infrared ... traditional and far-infrared saunas. , For traditional saunas, Finnleo is offering ... sauna wood, and Finnleo uses only European Grade A Nordic White Spruce from sustainably ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, Bohrer Brady, ... of Connecticut on behalf of a home health care worker who provided companionship services ... home health care workers employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... double board certified facial plastic surgeon specializing in both surgical and non-surgical treatments, ... The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained and ...
Breaking Medicine News(10 mins):